Medical Marijuana for Chronic Traumatic Encephalopathy (CTE) in Ohio

Chronic traumatic encephalopathy is one of Ohio’s recognized qualifying conditions for medical marijuana — and one with a diagnostic challenge that is unique among all conditions on the qualifying list. For Ohio patients and their families navigating what may be CTE, this page explains how the condition qualifies under Ohio law, what the research shows about cannabinoids in this context, and what realistic expectations look like.

Does CTE Qualify for Medical Marijuana in Ohio?

Yes. Chronic traumatic encephalopathy is explicitly listed as a qualifying condition under Ohio Revised Code Section 3796.01. A physician holding a Certificate to Recommend (CTR) issued by the State Medical Board of Ohio evaluates whether your documented condition and symptom picture support a medical marijuana recommendation.

The Most Important Thing Ohio CTE Patients Need to Understand

This is the context that virtually every competitor site overlooks — and it is the most critical piece of information for Ohio patients pursuing a medical marijuana evaluation for CTE.

CTE can currently only be definitively diagnosed by postmortem neuropathological examination of brain tissue. As documented in research published through PMC on CTE diagnostic criteria, today “chronic traumatic encephalopathy” refers exclusively to the tissue-based neuropathological diagnosis. The clinical syndrome associated with CTE pathology — the symptoms experienced by living patients — is known as Traumatic Encephalopathy Syndrome or TES.

What this means practically for Ohio patients is that no living person can receive a confirmed CTE diagnosis. A physician conducting your medical marijuana evaluation will be evaluating your clinical symptoms and history of repetitive head trauma — consistent with a TES presentation — rather than a definitive CTE diagnosis.

This is not a barrier to qualifying — Ohio law lists CTE as a qualifying condition and the evaluation process accounts for clinical presentations. It simply means being clear with your evaluating physician about your head trauma history and symptom picture, and understanding that what you are experiencing is being evaluated as a clinical syndrome rather than a confirmed neuropathological diagnosis.

What Is CTE and Who Is Most at Risk?

CTE is a progressive neurodegenerative disease characterized by the accumulation of hyperphosphorylated tau protein in the brain — caused by repetitive concussive and subconcussive blows to the head over time. As reviewed in research published through PMC on traumatic encephalopathy, the condition shares some pathological features with Alzheimer’s and Parkinson’s diseases but is specifically linked to a history of repeated head trauma.

Populations most commonly associated with CTE risk include contact sport athletes — particularly football players, boxers, hockey players, and soccer players — military veterans exposed to blast injuries, and individuals with a history of repeated traumatic brain injuries from any cause.

Symptoms associated with CTE pathology include memory loss and confusion, depression, anxiety, irritability and mood instability, impulsivity, paranoia, poor concentration, headaches, and over time cognitive decline. Symptoms typically appear years or decades after the period of head trauma rather than immediately.

What Does the Research Show About Cannabinoids and CTE?

The Biological Rationale

The case for cannabinoids in CTE rests primarily on their anti-inflammatory and neuroprotective properties — which are highly relevant to CTE pathology. Research published through PMC on cannabis therapeutics and neurology notes that the neuroprotective antioxidant effects of cannabinoids are particularly relevant in their ability to counteract glutamate excitotoxicity — a key mechanism of neuronal damage following traumatic brain injury that is also implicated in CTE pathogenesis.

The same review notes anecdotally that cannabis — particularly formulations combining THC and CBD — has been reported as helpful in managing CTE-associated symptoms including headache, nausea, insomnia, dizziness, agitation, and neuropsychiatric symptoms.

Research published through PMC examining cannabinoids in TBI and related neuropathologies — which specifically includes CTE as a repeated mTBI-associated neurodegenerative disorder — found that cannabinoids interact with neurons, microglia, and astrocytes and exert anti-inflammatory and neuroprotective effects that are highly relevant to TBI and CTE management.

What Has Not Yet Been Established in Human Trials

CTE-specific controlled clinical trials of cannabis do not yet exist — a consequence of the same diagnostic challenge discussed above. Because CTE can only be confirmed postmortem, it is impossible to design a traditional randomized controlled trial in CTE patients with confirmed diagnoses. What exists is a combination of preclinical research, anecdotal clinical evidence, and research on the overlapping TBI and neurodegenerative disease populations.

Medical marijuana does not treat CTE itself — it does not reverse tau accumulation, halt neurodegeneration, or alter disease course. It addresses the clinical symptoms associated with the condition. There is currently no disease-modifying treatment for CTE.

Which Symptoms Are Most Relevant for Medical Marijuana in CTE?

Based on the available research and clinical anecdotal evidence, the symptoms associated with CTE that medical marijuana most commonly addresses include:

Headaches and chronic pain — among the most consistently reported benefits in TBI and CTE-adjacent research, and one of the most common chronic symptoms in patients with repetitive head trauma history.

Sleep disruption — insomnia is a prominent CTE-associated symptom. Research on TBI and neurodegenerative populations consistently shows cannabinoids improve sleep quality as one of the first and most reliable symptom benefits.

Mood disturbance and anxiety — depression, anxiety, irritability, and mood instability are hallmark CTE symptoms. Cannabis-based medicines have shown improvements in anxiety and mood in adjacent neurodegenerative patient populations.

Agitation — clinical anecdote from neurology contexts suggests combined THC:CBD formulations may help with agitation in CTE — consistent with the agitation findings in Alzheimer’s and other neurodegenerative populations our Alzheimer’s condition page covers in more detail.

An Important Note on Suicide Risk in CTE

CTE is associated with significantly elevated rates of depression, impulsivity, and suicide risk in affected individuals. Research on CTE in athletes has found suicide to be among the most common causes of death in the affected population.

For Ohio CTE patients or their family members experiencing thoughts of self-harm or suicide, please reach out to the 988 Suicide and Crisis Lifeline by calling or texting 988. Medical marijuana is a symptom management option — it is not a mental health crisis intervention and should never delay emergency support for someone in crisis.

Given that a confirmed CTE diagnosis is not possible in living patients, the documentation picture for CTE evaluations is different from most other qualifying conditions:

Medical or neurological records documenting your history of repetitive head trauma — including records from sports participation, military service, or documented prior concussions or TBIs. Any neurological evaluation records documenting symptoms consistent with traumatic encephalopathy syndrome — including cognitive testing, psychiatric evaluation, or neuroimaging results. Current symptom documentation noting headaches, sleep disruption, mood changes, memory difficulties, or other symptoms you are seeking to manage. Current medication list for the OARRS check.

A thorough, honest description of your head trauma history and current symptom picture is the most important preparation for a CTE-related medical marijuana evaluation.

Getting Your Ohio CTE Medical Marijuana Evaluation

Ohio’s telemedicine evaluation is completed entirely online — no in-person visit required. A caregiver or family member may participate in the call alongside the patient — particularly important for CTE patients experiencing cognitive or behavioral symptoms that make independent communication difficult.

After a short intake form, a brief video consultation of 10 to 20 minutes with an Ohio-certified physician covers your head trauma history, current symptom picture, and current medications. If approved, your recommendation is submitted to the Ohio Patient & Caregiver Registry and your digital card is activated via email — valid at any licensed Ohio dispensary statewide. There is no charge if the physician determines you do not qualify.

If you are an Ohio CTE patient or caregiver and want to find out whether you qualify for the medical marijuana program, you can schedule your evaluation here.

Frequently Asked Questions

Sources

• Ohio Revised Code Section 3796.01 — Qualifying Medical Conditions — Ohio Laws
• State Medical Board of Ohio — Medical Marijuana Program — med.ohio.gov
• Ohio Patient & Caregiver Registry — Ohio Division of Cannabis Control
• Chronic Traumatic Encephalopathy: Criteria for Neuropathological Diagnosis — PMC / NIH
• Advances in Research in Traumatic Encephalopathy — PMC / NIH
• Cannabis Therapeutics and the Future of Neurology — PMC / NIH
• Cannabinoids in Traumatic Brain Injury and Related Neuropathologies — PMC / NIH